Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03697512
Title MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors International Extranodal Lymphoma Study Group (IELSG)
Indications

nodal marginal zone lymphoma

marginal zone B-cell lymphoma

splenic marginal zone lymphoma

MALT lymphoma

Therapies

Ibrutinib + Rituximab

Age Groups: senior | adult
Covered Countries ITA | FRA | BEL


No variant requirements are available.